Document is current
Any future updates will be listed below
-
Authors
Gillison, Maura
Awad, Mark
Twardowski, Przemyslaw
Sukari, Ammar
Johnson, Melissa
Lackner, Rudy
Stein, Mark
DeCillis, Arthur
Hernandez, Richard
Price, Jessica
Mancini, Kevin
Shainheit, Mara
Santone, Gabriella
Shukor, Syukri
Bicak, Ece
Vemulapalli, Vijetha
Tjon, Emily
Flechtner, Jessica
Davis, Thomas
Cohen, Roger
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03633110 at ClinicalTrials.govDocuments that mention this clinical trial
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0390
413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0413
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
521 GEN-009, a personalized neoantigen vaccine candidate, elicits diverse and durable immune responses associated with clinical efficacy outcomes
https://doi.org/10.1136/jitc-2021-sitc2021.521
526 Inhibigen<sup>TM</sup>-specific responses suppress anti-tumor immunity and promote tumor growth
https://doi.org/10.1136/jitc-2020-sitc2020.0526
485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.485
